- Home
- MIST vs CGTX Comparison
MIST vs CGTX Comparison
Compare MIST & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | CGTX |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.3M | 94.5M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MIST | CGTX |
|---|---|---|
| Price | $1.04 | $0.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $8.50 | $3.33 |
| AVG Volume (30 Days) | ★ 1.7M | 650.8K |
| Earning Date | 03-20-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,653.36 | N/A |
| Revenue Next Year | $12.32 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $0.22 |
| 52 Week High | $3.06 | $3.83 |
Technical Indicators
Market Signals| Indicator | MIST | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.45 | 27.39 |
| Support Level | N/A | $0.56 |
| Resistance Level | $2.01 | $0.87 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 0.00 | 9.60 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.